Dry eye disease (DED) is a complex multifactorial disease that affects an increasing number of patients worldwide. Close to 30% of the population has experienced dry eye (DE) symptoms and presented with some signs of the disease during their lifetime. The significant heterogeneity in the medical background of patients with DEs and in their sensitivity to symptoms renders a clear understanding of DED complicated. It has become evident over the past few years that DED results from an impairment of the ocular surface homeostasis. Hence, a holistic treatment approach that concomitantly addresses the different mechanisms that result in the destabilization of the tear film (TF) and the ocular surface would be appropriate. The goal of the present ...
In 2017 by the results of TFOS DEWS, dry eye syndrome (DES) was recognized as a disease that require...
Dry eye disease (DED) is a prevalent and multifactorial pathology of the ocular surface affecting 5-...
George Ousler III,1 Douglas K Devries,2 Paul M Karpecki,3 Joseph B Ciolino41Ora, Inc, Andover, MA, U...
Dry eye disease (DED) is the most common ocular surface disease, characterized by insufficient produ...
Components of the ocular surface synergistically contribute to maintaining and protecting a smooth r...
At the air-water interface, the tear film lipid layer (TFLL), a combination of lipids and proteins p...
The tear film represents the interface between the eye and the environment. The alteration of the de...
Objectives: The assessment of three commercially available artificial tear formulations for dry eye ...
AbstractDry eye disease (DED) is a complex, multifactorial pathology characterized by corneal epithe...
Artificial tears are the mainstay of dry eye disease management, but also have a role in corneal abr...
Dry eye disease (DED) is a multifactorial disease that manifests in patients with a variety of sympt...
A better understanding of the pathophysiology and etiology of dry eye disease leads to more efficien...
Dry eye disease is a common clinical condition whose aetiology and management challenges clinicians ...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
AbstractDry eye syndrome is a common tears and ocular surface multifactorial disease, described by c...
In 2017 by the results of TFOS DEWS, dry eye syndrome (DES) was recognized as a disease that require...
Dry eye disease (DED) is a prevalent and multifactorial pathology of the ocular surface affecting 5-...
George Ousler III,1 Douglas K Devries,2 Paul M Karpecki,3 Joseph B Ciolino41Ora, Inc, Andover, MA, U...
Dry eye disease (DED) is the most common ocular surface disease, characterized by insufficient produ...
Components of the ocular surface synergistically contribute to maintaining and protecting a smooth r...
At the air-water interface, the tear film lipid layer (TFLL), a combination of lipids and proteins p...
The tear film represents the interface between the eye and the environment. The alteration of the de...
Objectives: The assessment of three commercially available artificial tear formulations for dry eye ...
AbstractDry eye disease (DED) is a complex, multifactorial pathology characterized by corneal epithe...
Artificial tears are the mainstay of dry eye disease management, but also have a role in corneal abr...
Dry eye disease (DED) is a multifactorial disease that manifests in patients with a variety of sympt...
A better understanding of the pathophysiology and etiology of dry eye disease leads to more efficien...
Dry eye disease is a common clinical condition whose aetiology and management challenges clinicians ...
Purpose: To assess the six-month therapeutic profiles of lipid and non-lipid-based artificial tear s...
AbstractDry eye syndrome is a common tears and ocular surface multifactorial disease, described by c...
In 2017 by the results of TFOS DEWS, dry eye syndrome (DES) was recognized as a disease that require...
Dry eye disease (DED) is a prevalent and multifactorial pathology of the ocular surface affecting 5-...
George Ousler III,1 Douglas K Devries,2 Paul M Karpecki,3 Joseph B Ciolino41Ora, Inc, Andover, MA, U...